Aurinia Pharmaceuticals Earnings Perspective: Return On Capital Employed
Portfolio Pulse from Benzinga Insights
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported Q1 sales of $34.41 million and a loss of $26.21 million. The company's Return on Capital Employed (ROCE) was -0.07%, suggesting inefficient capital allocation. Q1 earnings per share were $-0.18, beating analyst predictions of $-0.22.
May 18, 2023 | 2:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aurinia Pharmaceuticals reported Q1 sales of $34.41 million and a loss of $26.21 million. The company's ROCE of -0.07% suggests inefficient capital allocation, which may negatively impact the stock price.
Aurinia Pharmaceuticals' Q1 sales increased compared to Q4, but the company still reported a loss. The negative ROCE of -0.07% indicates that the company is not effectively allocating its capital, which could negatively impact the stock price in the short term. However, the company beat analyst predictions for earnings per share, which may provide some support to the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100